Our results of KEGG and Hallmark by GSEA revealed that FRAS1, FREM1 and FREM2 can potentially impact cancer etiology or pathogenesis by functioning in oncogenic signalling pathways (TGF-β signaling, PI3K AKT mTOR signaling, Wnt-β catenin signaling, Kras signaling, Hedgehog signaling and Notch signaling) and metabolic pathways (Heme metabolism, Fatty acid metabolism, Bile acid metabolism, Xenobiotic metabolism). This evidence concerns the gene KRAS and cancer.